CT-P52

N/A

Report date: 2026/04/14 20:00:15

Base Information

Drug NameCT-P52

Drug Alias Nameixekizumab biosimilar (Celltrion)CT-P52

ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionInterleukin 17A inhibitors

TargetsInterleukin 17A

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesCelltrion Inc

China Registration ClassN/A

Active CompaniesCelltrion Inc

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

ATC CodeN/A